文献速递瓣膜外科

低危择期患者严重主动脉瓣狭窄的外科与经导管主动脉瓣置换:AVALON多中心注册研究分析

Surgical and transcatheter aortic valve replacement for severe aortic stenosis in low-risk elective patients: Analysis of the Aortic Valve Replacement in Elective Patients From the Aortic Valve Multicenter Registry.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-10-28

AVALON多中心注册研究比较2015至2019年低危择期患者经股动脉TAVI与SAVR的中期生存,倾向评分匹配后TAVI组329例、SAVR组593例,30天死亡率两组无显著差异,2年后SAVR生存获益(HR 0.70)。

要点

  • 匹配后30天死亡率TAVI组3.32% vs SAVR组3.03%,风险比1.10,无显著差异。
  • 2年时生存曲线开始分离,SAVR与死亡风险降低30%相关(HR 0.70)。
  • 作者认为需随机试验延长观察以确认低危择期患者中的这些发现。

核心结论

  • 本研究未显示TAVI与SAVR在术后前2年内的生存差异,此后SAVR与生存改善相关。
  • 作者认为需在低危择期手术患者中延长随机试验观察以确认这些发现并得出明确结论。

研究设计与样本

  • AVALON为多中心注册研究,比较2015至2019年间低危患者择期经股动脉TAVI与胸骨切开或微创入路SAVR。
  • 采用倾向评分匹配以1比3比例、卡钳值0.2为TAVI组确定SAVR对照。
  • 初始纳入2393例择期手术患者(SAVR 1765例,TAVI 629例),中位EuroSCORE II评分1.81(IQR 1.36至2.53)。
  • 中位随访2.72年(IQR 1.32至4.08,最长6.0年),匹配后得TAVI组329例和SAVR对照组593例。

主要发现

  • 匹配后30天死亡率TAVI组为329例中11例(3.32%),SAVR组为593例中18例(3.03%),风险比1.10(95%CI 0.52至2.37,P=0.801)。
  • 2年时生存曲线开始分离而有利于SAVR,SAVR与死亡风险降低30%相关(HR 0.70,95%CI 0.496至0.997,P=0.048)。

局限性

  • 原文结论指出需在低危择期手术患者中延长随机试验观察以确认这些发现并得出明确结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Transcatheter aortic valve implantation (TAVI) remains the preferred strategy for high-risk or elderly individuals with aortic valve (AV) stenosis who are not considered to be optimal surgical candidates. Recent evidence suggests that low-risk patients may benefit from TAVI as well. The current study evaluates midterm survival in low-risk patients undergoing elective surgical AV replacement (SAVR) versus TAVI. METHODS: The Aortic Valve Replacement in Elective Patients From the Aortic Valve Multicenter Registry (AVALON) compared isolated elective transfemoral TAVI or SAVR with sternotomy or minimally invasive approach in low-risk individuals performed between 2015 and 2019. Propensity score matching was conducted to determine SAVR controls for TAVI group in a 1-to-3 ratio with 0.2 caliper. RESULTS: A total of 2393 patients undergoing elective surgery (1765 SAVR and 629 TAVI) with median European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) score 1.81 (interquartile range [IQR], 1.36 to 2.53]) were initially included. Median follow-up was 2.72 years (IQR, 1.32-4.08; max 6.0). Propensity score matching returned 329 TAVI cases and 593 SAVR controls. Thirty-day mortality was 11 out of 329 (3.32%) in TAVI and 18 out of 593 (3.03%) in SAVR (risk ratio, 1.10; 95% CI, 0.52-2.37; P = .801) groups, respectively. At 2 years, survival curves began to diverge in favor of SAVR, which was associated with 30% lower mortality (hazard ratio, 0.70; 95% CI, 0.496-0.997; P = .048). CONCLUSIONS: Our data did not demonstrate a survival difference between TAVI and SAVR during the first 2 postprocedure years. After that time, SAVR is associated with improved survival. Extended observations from randomized trials in low-risk patients undergoing elective surgery are warranted to confirm these findings and draw definitive conclusions.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kowalówka AR, Kowalewski M, Wańha W, et al. Surgical and transcatheter aortic valve replacement for severe aortic stenosis in low-risk elective patients: Analysis of the Aortic Valve Replacement in Elective Patients From the Aortic Valve Multicenter Registry. J Thorac Cardiovasc Surg. 2022. PMID: 36424214. doi:10.1016/j.jtcvs.2022.10.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。